Navigation Links
Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
Date:7/30/2009

ent safety and response data from both cohorts during the first two quarters of 2010.

"ANA598 has demonstrated potent antiviral activity and good tolerability as a single agent in Phase I, as well as preclinical properties indicative of likely synergy when used clinically in combination regimens," said Steve Worland, Ph.D., President and CEO of Anadys. "We are now in a position to demonstrate the value of ANA598 when used in combination in a Phase II trial to treat hepatitis C patients. This trial incorporates several attractive features designed to further enhance the competitive position of ANA598, including twelve weeks of triple combination treatment and a randomized exploration of shortening the overall duration of HCV therapy in conjunction with ANA598 treatment."

About ANA598

ANA598 is a non-nucleoside inhibitor of the HCV RNA polymerase. Anadys has completed three Phase I clinical studies of ANA598 that have demonstrated potent antiviral activity and good tolerability. In a monotherapy study in naive genotype 1 patients, treatment with ANA598 for three days led to median declines in viral load ranging from 2.4 to 2.9 log10 in three separate dose groups. No patient at any dose level showed evidence of viral rebound while on ANA598, and there were no serious adverse events.

Anadys has completed dosing in two long-term chronic toxicology studies of ANA598 (26 weeks duration in rats and 39 weeks duration in monkeys). At the 13-week interim, the toxicology profile of ANA598 in both species was very favorable. A preliminary assessment of the results from the 26-week study in rats indicates a similar profile to that seen in rats at 13 weeks, in which the only adverse finding was a marginal decrease in the rate of weight gain in females at 1000 mg/kg, the highest dose tested. Complete results from both studies, including 39-week data from the monkey study, are expected at
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
2. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
3. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
4. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
5. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
6. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
7. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
8. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
9. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
10. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
11. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... ... August 26, 2015 , ... The 2015 Epigenomics & Metabolomics Meeting ... company Asymmetrex to share the first report on progress with its crowdsourcing ... counting adult tissue stem cells. , With a name like “H2A.Z asymmetry,” the new ...
(Date:8/25/2015)... ... August 25, 2015 , ... A ... are cancerous is described by University of Illinois researchers in the Journal ... photonics. , In “ Breast cancer diagnosis using spatial light interference microscopy ,” ...
(Date:8/25/2015)... , Aug. 25, 2015 Human Longevity, Inc. (HLI), ... Winham has joined the company as Chief Operating Officer. ... medical operations and technical experience, will report directly to HLI,s ... In this new role as COO, Winham will be responsible ... as well as all facility operations. HLI currently has three ...
(Date:8/25/2015)... ... August 25, 2015 , ... ... and rackmount computing infrastructure, today announced the launch of its next generation, ... latest system boasts two distinct, individually sledded workstation nodes in each 1U ...
Breaking Biology Technology:Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4Human Longevity, Inc. Hires Life Sciences Leader, Mark Winham, as Chief Operating Officer 2Cirrascale® Announces Next Generation High Density, Two-in-One GPU Rackmount Offering Perfect for High Performance Remote Workstations 2Cirrascale® Announces Next Generation High Density, Two-in-One GPU Rackmount Offering Perfect for High Performance Remote Workstations 3
... on RDEA119 at the 2007, AACR-NCI-EORTC Conference ... SAN FRANCISCO, Oct. 24 Ardea Biosciences,Inc. (Nasdaq: ... discovery and development of,small-molecule therapeutics for the treatment ... preclinical data on its lead MEK,inhibitor, RDEA119, at ...
... 24 The Interstate,Alliance for Stem Cell Research should ... future sessions, the Foundation for Taxpayer and,Consumer Rights (FTCR) ... of various state,stem cell programs, is meeting today and ... Alliance is still in its early stages, it is ...
... Emisphere,Technologies, Inc. (Nasdaq: EMIS ) today announced ... of Vice President, Nonclinical Development and,Applied Biology, effective ... the oversight and management of nonclinical drug efficacy ... design of,discovery projects. Dr. Riley will report directly ...
Cached Biology Technology:New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties 2New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties 3New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties 4Consumers Call On Interstate Stem Cell Group To Endorse Open Meetings 2Emisphere Technologies, Inc. Appoints Gary Riley as Vice President Nonclinical Development & Applied Biology 2Emisphere Technologies, Inc. Appoints Gary Riley as Vice President Nonclinical Development & Applied Biology 3Emisphere Technologies, Inc. Appoints Gary Riley as Vice President Nonclinical Development & Applied Biology 4
(Date:7/31/2015)... de julio de 2015 La 10 th ... por medio de BGI del 22 al 25 de octubre de ... Este año, la conferencia celebra su décimo aniversario. Desde ... en una de las reuniones anuales más influyentes del mundo ... reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... has filed provisional patent 62/198989 for ELECTRONIC ... highlights a method to advance crypto-currencies such as Bitcoin ... a common, uniform way to manage all payments.  ...
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 ... products and services for gene function analysis and ... CRISPR Guide RNA (sgRNA) Knockout Library targeting all ... to specifically and permanently "knock out" a gene,s ... library provides a high throughput screening tool so ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2
... for a good cause, there may be unintended consequences. ... the loss of wildlife habitat, particularly that of the ... ,from Michigan Technological University and The Nature Conservancy. ... of the journal BioScience , David Flaspohler, Joseph ...
... the sex chromosomes of several species of cichlid fish ... by which new sex chromosomes may evolve. In ... Science , biologists Thomas Kocher, Reade Roberts and ... genetic basis for two co-existing systems of sexual determination ...
... AMES, Iowa Plants and algae may be a ... ancient, finite hydrocarbons in fossil fuels, according to a ... Shanks. Shanks, Iowa State,s Manley R. Hoppe Professor ... hydrocarbons as a way to store carbon and energy. ...
Cached Biology News:In search of wildlife-friendly biofuels 2In search of wildlife-friendly biofuels 3East African cichlid fish offer new understanding of genetic basis of sex determination 2Iowa State researchers looking for catalyst that allows plants to produce hydrocarbons 2
Opticon continuous fluorescence detector; includes optical base, analysis software, computer and monitor (this is an accessory for the DNA Engine thermal cyclers which must be ordered seperately)...
Hybridizer (220 V) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
... in vascular proliferation, adhesion, and wound repair ... cell adhesion receptors consists of at least ... and b subunit that associate in a ... of the integrin family are based upon ...
... exchange media are rigid macroporous hydrophilic media. ... rates at moderate pressures, while the macroporous ... the hydrophilic matrix reduces nonspecific binding. Macro-Prep ... anion exchanger with very high flow rates ...
Biology Products: